Cargando…

Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice

OBJECTIVES: Spinal muscular atrophy (SMA) is a devastating motor neuron disorder caused by homozygous loss of the survival motor neuron 1 (SMN1) gene and insufficient functional SMN protein produced by the SMN2 copy gene. Additional genetic protective modifiers such as Plastin 3 (PLS3) can counterac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strathmann, Eike A., Peters, Miriam, Hosseinibarkooie, Seyyedmohsen, Rigo, Frank W., Bennett, C. Frank, Zaworski, Phillip G., Chen, Karen S., Nothnagel, Michael, Wirth, Brunhilde
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126849/ https://www.ncbi.nlm.nih.gov/pubmed/30188931 http://dx.doi.org/10.1371/journal.pone.0203398

Ejemplares similares

CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis
por: Janzen, Eva, et al.
Publicado: (2018)

Plastin 3 in health and disease: a matter of balance
por: Wolff, Lisa, et al.
Publicado: (2021)

Antisense-based therapy for the treatment of spinal muscular atrophy
por: Rigo, Frank, et al.
Publicado: (2012)

High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed SMN2 Splicing in Patient Fibroblasts
por: Wijaya, Yogik Onky Silvana, et al.
Publicado: (2022)

Genetic modifiers ameliorate endocytic and neuromuscular defects in a model of spinal muscular atrophy
por: Walsh, Melissa B., et al.
Publicado: (2020)

Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon
por: Hua, Yimin, et al.
Publicado: (2007)

Improved Antisense Oligonucleotide Design to Suppress Aberrant SMN2 Gene Transcript Processing: Towards a Treatment for Spinal Muscular Atrophy
por: Mitrpant, Chalermchai, et al.
Publicado: (2013)

Antisense Oligonucleotide-Mediated Terminal Intron Retention of the SMN2 Transcript
por: Flynn, Loren L., et al.
Publicado: (2018)

Biomarker for Spinal Muscular Atrophy: Expression of SMN in Peripheral Blood of SMA Patients and Healthy Controls
por: Czech, Christian, et al.
Publicado: (2015)

Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides
por: Ward, Amanda J., et al.
Publicado: (2014)

Molecular Crosstalk Between Non-SMN-Related and SMN-Related Spinal Muscular Atrophy
por: Šoltić, Darija, et al.
Publicado: (2020)

Efficient SMN Rescue following Subcutaneous Tricyclo-DNA Antisense Oligonucleotide Treatment
por: Robin, Valérie, et al.
Publicado: (2017)

Long-Term SMN- and Ncald-ASO Combinatorial Therapy in SMA Mice and NCALD-ASO Treatment in hiPSC-Derived Motor Neurons Show Protective Effects
por: Muiños-Bühl, Anixa, et al.
Publicado: (2023)

Mitochondrial Dysfunction in Spinal Muscular Atrophy
por: Zilio, Eleonora, et al.
Publicado: (2022)

Therapeutic strategies for spinal muscular atrophy: SMN and beyond
por: Bowerman, Melissa, et al.
Publicado: (2017)

SMN post-translational modifications in spinal muscular atrophy
por: Riboldi, Giulietta M., et al.
Publicado: (2023)

Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides
por: Wang, Zhenxun, et al.
Publicado: (2012)

Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
por: Zhou, Haiyan, et al.
Publicado: (2020)

Plastin 3 rescues BDNF-TrkB signaling in spinal muscular atrophy
por: Ramsey, Arren, et al.
Publicado: (2023)

CORRIGENDUM to Molecular Crosstalk Between Non-SMN-Related and SMN-Related Spinal Muscular Atrophy
Publicado: (2020)

The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
por: Hensel, Niko, et al.
Publicado: (2020)

Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening – Opportunity or Burden?(1)
por: Müller-Felber, Wolfgang, et al.
Publicado: (2020)

Therapy Development for Spinal Muscular Atrophy in SMN Independent Targets
por: Tsai, Li-Kai
Publicado: (2012)

A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy
por: Keil, Jeffrey M, et al.
Publicado: (2014)

Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
por: Scoles, Daniel R., et al.
Publicado: (2017)

Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides
por: Scharner, Juergen, et al.
Publicado: (2020)

Lysine-Less Variants of Spinal Muscular Atrophy SMN and SMNΔ7 Proteins Are Degraded by the Proteasome Pathway
por: Sánchez-Lanzas, Raúl, et al.
Publicado: (2017)

Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy
por: Bouwman, Linde F., et al.
Publicado: (2021)

SMN1 dosage analysis in spinal muscular atrophy from India
por: Kesari, Akanchha, et al.
Publicado: (2005)

Modeling spinal muscular atrophy in Drosophila links Smn to FGF signaling
por: Sen, Anindya, et al.
Publicado: (2011)

Deletion of SMN and NAIP genes in Korean patients with spinal muscular atrophy.
por: Shin, S., et al.
Publicado: (2000)

The Spinal Muscular Atrophy Disease Protein SMN Is Linked to the Golgi Network
por: Ting, Chen-Hung, et al.
Publicado: (2012)

25 years of the SMN genes: the Copernican revolution of spinal muscular atrophy
por: Tiziano, Francesco Danilo, et al.
Publicado: (2020)

SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy
por: Valsecchi, Valeria, et al.
Publicado: (2023)

Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment
por: Sintusek, Palittiya, et al.
Publicado: (2016)

A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
por: Biliouris, Konstantinos, et al.
Publicado: (2018)

Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients
por: Müschen, Lars Hendrik, et al.
Publicado: (2021)

Antisense oligonucleotides correct the familial dysautonomia splicing defect in IKBKAP transgenic mice
por: Sinha, Rahul, et al.
Publicado: (2018)

Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model
por: Sheng, Lei, et al.
Publicado: (2020)

Plastin 3 Expression Does Not Modify Spinal Muscular Atrophy Severity in the ∆7 SMA Mouse
por: McGovern, Vicki L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qvtda6denvrnop6iee49fa3j4v